US-based biopharmaceutical firm Paratek Pharmaceuticals has reported positive top-line results from its Phase III clinical trial of omadacycline to treat community-acquired bacterial pneumonia (CABP) patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Omadacycline is an investigational oral and intravenous (IV) broad spectrum antibiotic currently being designed for use as empiric monotherapy for patients with community-acquired bacterial infections.

The results from the trial indicated that all the US Food and Drug Administration (FDA) primary and secondary endpoints, as well as European Medical Agency (EMA) co-primary endpoints have been met.

The global, randomised, double-blind, active-controlled, multi-centre Phase III OPTIC trial evaluated the safety and efficacy of once-daily, IV-to-oral omadacycline compared to IV-to-oral moxifloxacin in 774 adult patients.

See Also:

Paratek chairman and chief executive officer Michael Bigham said: “This successful study demonstrates the potential of omadacycline to treat community-acquired bacterial pneumonia, a significant and serious health issue.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"This successful study demonstrates the potential of omadacycline to treat community-acquired bacterial pneumonia, a significant and serious health issue."

“This Phase III study in pneumonia, along with our previously announced successful Phase III study in skin infections, satisfy the regulatory filing requirements of our special protocol assessment with the FDA."

Omadacycline has met the primary endpoint of statistical non-inferiority (NI) and secondary endpoints at the post-treatment evaluation (PTE) visit five to ten days post-treatment completion.

The drug was also found to be safe and well-tolerated with a high response rate, and met statistical non-inferiority compared to moxifloxacin.

Paratek plans to submit a new drug application (NDA) to the FDA in the first quarter of next year and to EMA late next year.

Image: Lungs with community-acquired pneumonia. Photo: courtesy of Jtechr/Wikipedia.